Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Get the full story at […]
Glaukos
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
Glaukos stock dips on big Q2 earnings miss
Glaukos (NYSE:GKOS) shares were down this morning on second-quarter results that missed the consensus earnings forecast. The Aliso Viejo, California–based glaucoma treatment developer posted losses of $45.5 million, or 96¢ per share, on sales of $72.7 million for the three months ended June 30, 2022, for a bottom-line slide deeper into the red on a […]
Glaukos posts Street-beating Q1 results
Glaukos (NYSE:GKOS) this week posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, California-based company reported profits of $5.4 million, or 11¢ per share, on sales of $67.7 million for the three months ended March 31, for a sales loss of -0.42% compared with Q1 2021. Adjusted to exclude one-time items, […]
Glaukos rises on Street-beating Q4
Glaukos (NYSE:GKOS) shares ticked up today on fourth-quarter results that beat the consensus forecast. The San Clemente, California-based eye disease treatment developer posted losses of $21.9 million, or losses per share of 47¢, on sales of $73.2 million for the three months ended Dec. 31, 2021, for a bottom-line slide deeper into the red on […]
Glaukos announces executive leadership changes
Glaukos this week announced several executive leadership changes that will take place on April 1. Joseph Gilliam is appointed as president and COO. He previously served as the CFO and SVP of corporate development for the San Clemente, California-based ophthalmic medtech and pharma company since 2017. Here are Glaukos’ new executive committee appointments: Chris Calcaterra […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
FDA clears Glaukos’ iPrime
Glaukos (NYSE:GKOS) announced that it received FDA 510(k) clearance for its iPrime viscodelivery system. San Clemente, California-based Glaukos designed the Prime viscodelivery system as a sterile, single-use, minimally invasive device for delivering viscoelastic fluid during ophthalmic surgery. Get the full story at our sister site, Drug Delivery Business News.
Glaukos announces licensing deal with Attillaps for pharmaceutical compounds
Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Attillaps for its library of pharmaceutical compounds. San Clemente, California-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites — the root cause of Demodex blepharitis […]
Ivantis to pay $60M in patent litigation settlement with Glaukos
Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. Get the full […]
